Investment
Features
FeesSafety
Academy
More
Pluang+

Compare InMode Ltd (INMD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

InMode LtdTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

InMode Ltd vs Neurocrine Biosciences Inc — how do they compare? InMode Ltd trades at $15.16 (market cap $872.08M), while Neurocrine Biosciences Inc trades at $158.62 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 18.9× InMode Ltd's market cap. Which is the better fit depends on your goals.

INMDNBIX
Market Cap
$872.08M$16.46B
Sector
TechnologyHealth
52-Week High
$16.62$185.50
52-Week Low
$12.76$123.10
Enterprise Value
$375.42M$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

InMode Ltd

InMode (INMD) trades at $15.17, down slightly by 0.13% today, with neutral technical signals and mixed earnings performance. The company maintains strong profitability with 76.52% gross margins and 20.69% net income margins, though Q1 2026 earnings missed expectations. Recent news highlights acquisition interest from Steel Partners at $16.75 per share and ongoing shareholder activism, creating both opportunity and uncertainty around corporate governance and valuation.

The stock presents a value opportunity with low P/E (12.52) and EV/EBITDA (5.37) multiples, but faces risks from earnings volatility, shareholder disputes, and potential undervaluation concerns. Analyst consensus leans neutral with 45% buy ratings, while technical indicators suggest range-bound trading near key support at $15. Investment appeal hinges on resolution of acquisition talks and sustained execution amid competitive pressures.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About InMode Ltd

InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.

Read more on INMD

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX